Glenmark becomes fifth generic to be charged with US antitrust violations
02-07-2020
Par avoids pay-for-delay suit after court accepts payment was ‘fair’
10-03-2020
Tada Images / Shutterstock.com
Pharmaceutical companies MSD (known as 'Merck & Co' in the US) and Glenmark have argued that the class certification of wholesale buyers of cholesterol drug Zetia (ezetimibe) should be reversed because the circumstances of the class members do not justify an award of class status.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
MSD, Glenmark, generic competition, pay-for-delay, Zetia, cholesterol drug, ezetimibe, class certification, settlement, wholesalers, patent infringement
